285 related articles for article (PubMed ID: 28255795)
1.
Sathekge M; Knoesen O; Meckel M; Modiselle M; Vorster M; Marx S
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1099-1100. PubMed ID: 28255795
[No Abstract] [Full Text] [Related]
2. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
Kratochwil C; Bruchertseifer F; Giesel FL; Weis M; Verburg FA; Mottaghy F; Kopka K; Apostolidis C; Haberkorn U; Morgenstern A
J Nucl Med; 2016 Dec; 57(12):1941-1944. PubMed ID: 27390158
[TBL] [Abstract][Full Text] [Related]
3. Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with
Kratochwil C; Bruchertseifer F; Rathke H; Bronzel M; Apostolidis C; Weichert W; Haberkorn U; Giesel FL; Morgenstern A
J Nucl Med; 2017 Oct; 58(10):1624-1631. PubMed ID: 28408529
[TBL] [Abstract][Full Text] [Related]
4. 225Ac-PSMA-617 Radioligand Posttherapy Imaging in Metastatic Castrate-Resistant Prostate Cancer Patient Using 3 Photopeaks.
Vatsa R; Sood A; Vadi SK; Das CK; Kaur K; Parmar M; Mittal BR
Clin Nucl Med; 2020 Jun; 45(6):437-438. PubMed ID: 32366786
[TBL] [Abstract][Full Text] [Related]
5. Targeted alpha therapy of mCRPC: Dosimetry estimate of
Kratochwil C; Schmidt K; Afshar-Oromieh A; Bruchertseifer F; Rathke H; Morgenstern A; Haberkorn U; Giesel FL
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):31-37. PubMed ID: 28891033
[TBL] [Abstract][Full Text] [Related]
6. Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
Schlenkhoff CD; Knüpfer E; Essler M; Ahmadzadehfar H
Clin Nucl Med; 2016 Jul; 41(7):572-3. PubMed ID: 26909718
[TBL] [Abstract][Full Text] [Related]
7. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
[TBL] [Abstract][Full Text] [Related]
8.
Rahbar K; Ahmadzadehfar H; Boegemann M
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):513-514. PubMed ID: 29164300
[No Abstract] [Full Text] [Related]
9. Exceptional 4-year response to
Gafita A; Wang H; Tauber R; D'Alessandria C; Weber WA; Eiber M
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2212-2213. PubMed ID: 31273434
[No Abstract] [Full Text] [Related]
10. Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
Roll W; Bräuer A; Weckesser M; Bögemann M; Rahbar K
Clin Nucl Med; 2018 Oct; 43(10):755-756. PubMed ID: 30036254
[TBL] [Abstract][Full Text] [Related]
11. Treatment of brain metastases of castration-resistant prostate cancer with
Sathekge MM; Bruchertseifer F; Lawal IO; Vorster M; Knoesen O; Lengana T; Boshomane TG; Mokoala KK; Morgenstern A
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1756-1757. PubMed ID: 31115638
[No Abstract] [Full Text] [Related]
12. Results of a Prospective Phase 2 Pilot Trial of
Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM
Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003
[TBL] [Abstract][Full Text] [Related]
13. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer.
Rahbar K; Bode A; Weckesser M; Avramovic N; Claesener M; Stegger L; Bögemann M
Clin Nucl Med; 2016 Jul; 41(7):522-8. PubMed ID: 27088387
[TBL] [Abstract][Full Text] [Related]
14. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
Müller C; Umbricht CA; Gracheva N; Tschan VJ; Pellegrini G; Bernhardt P; Zeevaart JR; Köster U; Schibli R; van der Meulen NP
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1919-1930. PubMed ID: 31134301
[TBL] [Abstract][Full Text] [Related]
15. Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617.
Wei X; Schlenkhoff C; Sopora C; Essler M; Ahmadzadehfar H
Clin Nucl Med; 2016 Nov; 41(11):894-895. PubMed ID: 27607162
[TBL] [Abstract][Full Text] [Related]
16. SNMMI Consensus Statement on Patient Selection and Appropriate Use of
Hope TA; Antonarakis ES; Bodei L; Calais J; Iravani A; Jacene H; Koo PJ; Morgans AK; Osborne JR; Tagawa ST; Taplin ME; Sartor O; Morris MJ
J Nucl Med; 2023 Sep; 64(9):1417-1423. PubMed ID: 37290800
[No Abstract] [Full Text] [Related]
17. A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?
Gupta M; Karthikeyan G; Choudhury PS; Babu Koyyala VP; Sharma M; Jain P; Talwar V; Singh A; Rawal S
Cancer Invest; 2020 Sep; 38(8-9):486-492. PubMed ID: 32804008
[TBL] [Abstract][Full Text] [Related]
18. Response to Concomitant Enzalutamide and 177Lu-PSMA-617 Radioligand Therapy in ATM-Mutated Metastatic Castration Resistant Prostate Cancer.
Satapathy S; Das CK; Parihar AS; Sood A; Mittal BR
Clin Nucl Med; 2021 Jul; 46(7):582-583. PubMed ID: 33630794
[TBL] [Abstract][Full Text] [Related]
19. Delayed response after repeated
Rahbar K; Bögeman M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):243-246. PubMed ID: 29134280
[TBL] [Abstract][Full Text] [Related]
20. Influence of short-term dexamethasone on the efficacy of
Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
